Daily Bulletin

Men's Weekly

.

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

  • Written by PR Newswire Asia - Daily Bulletin Au RSS

- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically

- Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma

MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ -- PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular...

Read more: PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant...

Business News

Improving Leadership Skills Through Business Coaching

Good leadership has nothing to do with knowing everything. It's about being open to learning, making intelligent choices, and getting the best out of those around you. No matter if you work with a ...

Daily Bulletin - avatar Daily Bulletin

How to Choose the Right Business Networking Event in Brisbane for You

In Brisbane, there’s no shortage of business networking events that can help you grow your business, connect with key professionals, and discover new opportunities.  But with so many options, how d...

Daily Bulletin - avatar Daily Bulletin

The Importance of Hiring Tax Accountants in Melbourne

Whether you’re a small business owner, a freelancer, or an individual, finding the right tax accountants Melbourne can make all the difference in ensuring compliance, minimizing liabilities, and max...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals